Navigate / search

Return on Investment to Accelerate Research Growth

The George Washington University (GW) has sold a portion of its royalty rights for a drug originally developed at the School of Medicine and Health Sciences (SMHS), officials announced in August 2019. The move allows GW to reinvest significant funds into strategic priorities in academics, research, and innovation, accelerating its growth as a preeminent research university. Read more